Top

Published in:

01-12-2005 | Original Paper

Etidronate does not suppress periprosthetic bone loss following cemented hip arthroplasty

Authors: S. K. Fokter, R. Komadina, A. Repše-Fokter, S. A. Yerby, A. Kocijančič, J. Marc

Published in: International Orthopaedics | Issue 6/2005

Abstract

Periprosthetic bone loss after arthroplasty may threaten prosthesis survival. The current study investigated the effect of etidronate therapy on periprosthetic, contralateral hip, and spine bone mineral density (BMD) in a one-year, prospective, randomized, double-blind study on 46 patients after cemented hip arthroplasty. BMD was measured with dual-energy X-ray absorptiometry (DXA). There were no significant differences between mean BMD measurements of the etidronate and placebo groups, with the exception of the mean percent change in the spine at six months and 12 months and in Gruen zone 3 at six months; in all three cases, the etidronate group had significantly greater mean values. These findings suggest that cyclic etidronate therapy has no significant effect in suppressing periprosthetic bone loss following cemented hip arthroplasty.

Cohen B, Rushton N (1995) Accuracy of DEXA measurement of bone mineral density after total hip arthroplasty. J Bone Joint Surg Br 77:479–483PubMed

Cranney A, Guyatt G, Krolicki N, Welch V, Griffith L, Adachi JD, Shea B, Tugwell P, Wells G (2001) A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis. Osteoporos Int 12:140–151CrossRefPubMed

Duncan CP, Masterson EL, Masri BA (1998) Impaction allografting with cement for the management of femoral bone loss. Orthop Clin North Am 29:297–305CrossRefPubMed

Dunn CJ, Fitton A, Sorkin EM (1994) Etidronic acid: a review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs Aging 5:446–474PubMedCrossRef

Fleisch HA (1997) Bisphosphonates: preclinical aspects and use in osteoporosis. Ann Med 29:55–62PubMed

Gruen TA, McNeice GM, Amstutz HC (1979) “Modes of failure” of cemented stem-type femoral components: a radiographic analysis of loosening. Clin Orthop Relat Res 141:17–27PubMed

Harris ST, Watts NB, Jackson RD, Genant HK, Wasnich RD, Ross P, Miller PD, Licata AA, Chesnut CH III (1993) Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 95:557–567CrossRefPubMed

Kroger H, Miettinen H, Arnala I, Koski E, Rushton N, Suomalainen O (1996) Evaluation of periprosthetic bone using dual-energy x-ray absorptiometry: precision of the method and effect of operation on bone mineral density. J Bone Miner Res 11:1526–1530PubMedCrossRef

Kroger H, Venesmaa P, Jurvelin J, Miettinen H, Suomalainen O, Alhava E (1998) Bone density at the proximal femur after total hip arthroplasty. Clin Orthop Relat Res 352:66–74CrossRefPubMed

10.

Lewallen DG, Berry DJ (1998) Periprosthetic fracture of the femur after total hip arthroplasty: treatment and results to date. Instr Course Lect 47:243–249PubMed

11.

Nehme A, Maalouf G, Tricoire JL, Giordano G, Chiron P, Puget J (2003) Effect of alendronate on periprosthetic bone loss after cemented primary total hip arthroplasty: a prospective randomized study. Rev Chir Orthop Reparatrice Appar Mot 89:593–598PubMed

12.

Oh I, Harris WH (1978) Proximal strain distribution in the loaded femur: an in vitro comparison of the distributions in the intact femur and after insertion of different hip-replacement femoral components. J Bone Joint Surg Am 60:75–85PubMed

13.

Pols HA, Felsenberg D, Hanley DA, Stepan J, Munoz-Torres M, Wilkin TJ, Qin-sheng G, Galich AM, Vandormael K, Yates AJ, Stych B (1999) Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 9:461–468PubMedCrossRef

14.

Reiter A, Sabo D, Simank HG, Buchner T, Seidel M, Lukoschek M (1997) Periprosthetic mineral density in cement-free hip replacement arthroplasty. Z Orthop Ihre Grenzgeb 135:499–504PubMed

15.

Russell RG, Rogers MJ (1999) Bisphosphonates: from the laboratory to the clinic and back again. Bone 25:97–106CrossRefPubMed

16.

Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH (1990) Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 322:1265–1271PubMedCrossRef

17.

Trevisan C, Bigoni M, Randelli G, Marinoni EC, Peretti G, Ortolani S (1997) Periprosthetic bone density around fully hydroxyapatite coated femoral stem. Clin Orthop Relat Res 340:109–117CrossRefPubMed

18.

Tucci JR, Tonino RP, Emkey RD, Peverly CA, Kher U, Santora AC, 2nd (1996) Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 101:488–501CrossRefPubMed

19.

Venesmaa PK, Kroger HP, Miettinen HJ, Jurvelin JS, Suomalainen OT, Alhava EM (2001) Monitoring of periprosthetic BMD after uncemented total hip arthroplasty with dual-energy X-ray absorptiometry: a 3-year follow-up study. J Bone Miner Res 16:1056–1061PubMedCrossRef

20.

Venesmaa PK, Kroger HP, Miettinen HJ, Jurvelin JS, Suomalainen OT, Alhava EM (2001) Alendronate reduces periprosthetic bone loss after uncemented primary total hip arthroplasty: a prospective randomized study. J Bone Miner Res 16:2126–2131PubMedCrossRef

21.

Venesmaa PK, Kroger HP, Jurvelin JS, Miettinen HJ, Suomalainen OT, Alhava EM (2003) Periprosthetic bone loss after cemented total hip arthroplasty: a prospective 5-year dual energy radiographic absorptiometry study of 15 patients. Acta Orthop Scand 74:31–36CrossRefPubMed

22.

Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC III, Yanover MJ (1990) Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323:73–79PubMedCrossRef

23.

Wilkinson JM, Peel NF, Elson RA, Stockley I, Eastell R (2001) Measuring bone mineral density of the pelvis and proximal femur after total hip arthroplasty. J Bone Joint Surg Br 83:283–288CrossRefPubMed

24.

Wilkinson JM, Stockley I, Peel NF, Hamer AJ, Elson RA, Barrington NA, Eastell R (2001) Effect of pamidronate in preventing local bone loss after total hip arthroplasty: a randomized, double-blind, controlled trial. J Bone Miner Res 16:556–564PubMedCrossRef

25.

Yamaguchi K, Masuhara K, Yamasaki S, Nakai T, Fuji T (2003) Cyclic therapy with etidronate has a therapeutic effect against local osteoporosis after cementless total hip arthroplasty. Bone 33:144–149CrossRefPubMed

Title: Etidronate does not suppress periprosthetic bone loss following cemented hip arthroplasty
Authors: S. K. Fokter
R. Komadina
A. Repše-Fokter
S. A. Yerby
A. Kocijančič
J. Marc
Publication date: 01-12-2005
Publisher: Springer-Verlag
Published in: International Orthopaedics / Issue 6/2005
Print ISSN: 0341-2695
Electronic ISSN: 1432-5195
DOI: https://doi.org/10.1007/s00264-005-0018-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Etidronate does not suppress periprosthetic bone loss following cemented hip arthroplasty

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2005

Evaluation of cervical spondylotic myelopathy using somatosensory-evoked potentials

Casting versus surgical fixation for grade IIIA open tibial diaphysial fractures in children: effect on the rate of infection and the need for secondary surgical procedures to promote bone union

Particle migration and gap healing around trabecular metal implants

Local flap coverage following posteromedial release in clubfoot surgery in older children

Surgical treatment of brachial plexus injuries in adults

Antero-medialisation of the tibial tubercle for patellar instability